Cite
HARVARD Citation
Mcsheehy, P. et al. (n.d.). Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models. European journal of cancer. pp. S25-S26. [Online].